Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance
- PMID: 16793350
- DOI: 10.1016/j.jcf.2006.05.011
Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance
Abstract
Background: Achromobacter xylosoxidans is increasingly cultured in sputum from cystic fibrosis (CF) patients; nevertheless, there are few published data on the clinical impact of this infection or chronic colonisation.
Methods: Relying on DNA fingerprinting techniques we studied the prevalence of A. xylosoxidans in our CF population. In a retrospective case control study the clinical status of patients with at least 3 sputum cultures positive for A. xylosoxidans over at least 9 months, at the moment of the first positive culture and during the period of colonisation were compared to age (+/-1 year), gender and to Pseudomonas aeruginosa colonisation controlled CF patients who had never A. xylosoxidans positive sputum cultures.
Results: The prevalence of patients with at least one positive A. xylosoxidans culture was 17.9%. 5.3% of the patients fulfilled the criteria of our definition of colonisation. Colonised patients had a median age of 20 years (range 11-27 years) and a mean colonisation period of 1.5 (+/-0.9) years. At the moment of the first positive culture we found significantly lower Bhalla scores on HRCT scans of the lungs (11+/-3 versus 16+/-3, p<0.002), lower Brasfield chest X-ray scores (14+/-3 versus 18+/-3, p<0.019), lower FVC values (70%+/-22 versus 94%+/-12, p<0.017) and lower FEV(1) values (55%+/-32 versus 78%+/-23, p=0.123), although the latter did not reach significance. There was no significant difference in body mass index (BMI) (18.7+/-3 kg/m2 versus 19.6+/-3 kg/m2, p=0.8). Over the study period A. xylosoxidans-colonised patients did have more need for intravenous antibiotic treatment courses (19 versus 5, p<0.001); nevertheless, there was no significant difference in lung function decline over the study period (FVC: -6.25+/-12.34% versus -5.62+/-8.30%, p 0.77, FEV1: -5.62+/-8.30% versus -1.87+/-11.58%, p<0.47).
Conclusions: The prevalence of A. xylosoxidans infection or colonisation is probably underestimated. Colonised patients are mostly older, with more pronounced lung damage and lower lung function values. Although there was more need for intravenous antibiotic treatment courses, no faster decline in lung function was observed in A. xylosoxidans positive patients.
Similar articles
-
Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients.J Cyst Fibros. 2010 Jan;9(1):51-8. doi: 10.1016/j.jcf.2009.10.005. Epub 2009 Nov 25. J Cyst Fibros. 2010. PMID: 19939747
-
Alcaligenes infection in cystic fibrosis.Pediatr Pulmonol. 2002 Aug;34(2):101-4. doi: 10.1002/ppul.10143. Pediatr Pulmonol. 2002. PMID: 12112775
-
Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study.J Cyst Fibros. 2006 Dec;5(4):245-51. doi: 10.1016/j.jcf.2006.04.002. Epub 2006 Jun 13. J Cyst Fibros. 2006. PMID: 16777495
-
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.Clin Microbiol Infect. 2005 Sep;11(9):690-703. doi: 10.1111/j.1469-0691.2005.01217.x. Clin Microbiol Infect. 2005. PMID: 16104983 Review.
-
Emerging and unusual gram-negative infections in cystic fibrosis.Semin Respir Crit Care Med. 2007 Jun;28(3):312-21. doi: 10.1055/s-2007-981652. Semin Respir Crit Care Med. 2007. PMID: 17562501 Review.
Cited by
-
Achromobacter xylosoxidans airway infection is associated with lung disease severity in children with cystic fibrosis.ERJ Open Res. 2021 May 31;7(2):00076-2021. doi: 10.1183/23120541.00076-2021. eCollection 2021 Apr. ERJ Open Res. 2021. PMID: 34084788 Free PMC article.
-
Sepsis Caused by Achromobacter Xylosoxidans in a Child with Cystic Fibrosis and Severe Lung Disease.Am J Case Rep. 2016 Aug 8;17:562-6. doi: 10.12659/ajcr.896577. Am J Case Rep. 2016. PMID: 27498677 Free PMC article.
-
Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients.Respir Res. 2010 Oct 8;11(1):140. doi: 10.1186/1465-9921-11-140. Respir Res. 2010. PMID: 20932301 Free PMC article.
-
Microbiology of Cystic Fibrosis Airway Disease.Semin Respir Crit Care Med. 2019 Dec;40(6):727-736. doi: 10.1055/s-0039-1698464. Epub 2019 Dec 30. Semin Respir Crit Care Med. 2019. PMID: 31887768 Free PMC article. Review.
-
Upper versus lower airway microbiome and metagenome in children with cystic fibrosis and their correlation with lung inflammation.PLoS One. 2019 Sep 19;14(9):e0222323. doi: 10.1371/journal.pone.0222323. eCollection 2019. PLoS One. 2019. PMID: 31536536 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical